Posted inBiotechnology
Posted inBiotechnology
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
A phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts…







